Welcome to our dedicated page for Crescita Therape news (Ticker: CRRTF), a resource for investors and traders seeking the latest updates and insights on Crescita Therape stock.
Crescita Therapeutics Inc. (OTC US: CRRTF; TSX: CTX) is a Canadian commercial dermatology company that regularly issues detailed news releases about its operations, financial performance and strategic agreements. As a company with in-house R&D and manufacturing capabilities and three defined segments—Commercial Skincare, Licensing and Royalties, and Manufacturing and Services—its news flow covers a range of topics relevant to investors and industry observers.
Readers of this news page can expect recurring coverage of quarterly and annual financial results, where Crescita reports revenue by segment, gross profit, operating expenses, net income or loss, and non-IFRS measures such as EBITDA and Adjusted EBITDA. These releases often explain how performance in the Skincare, Licensing and Manufacturing segments contributed to overall results and describe factors such as contract manufacturing volumes, licensing payments related to Pliaglis®, and sales of branded skincare products.
Crescita’s news also highlights licensing and distribution developments for Pliaglis, including commercialization and development license agreements, exclusive distribution agreements in specific territories, and changes such as the mutual termination of a licensing agreement with Croma Pharma GmbH and the resulting reversion of rights to Crescita. Updates on regulatory pathways for Pliaglis in markets such as China, through partners responsible for clinical trials and approvals, appear in these communications.
Another recurring theme is contract manufacturing and strategic asset acquisitions. The company has announced an amended contract manufacturer supply agreement with a global skincare client, an exclusive manufacturing and supply agreement with a Canadian healthcare services provider for sanitary products, and acquisitions of assets from Occy Laboratoire Inc. and Laboratoire Provence-Canada Inc. News items describe how these arrangements affect manufacturing volumes, plant utilization and the product and client base.
Additional releases cover corporate actions and governance, such as approvals and activity under normal course issuer bids, results of annual general and special meetings of shareholders, and participation in investor conferences. For ongoing insight into Crescita’s financial performance, partnerships and manufacturing activities, this page aggregates the company’s official news in one place.
Crescita (OTC: CRRTF) reported Q3-2025 results for the quarter ended September 30, 2025. Revenue was $5,393K, up $1,799K vs Q3-2024; gross profit was $2,855K (52.9% margin). The company recorded net income $753K versus a net loss of $(1,036)K in Q3-2024 and Adjusted EBITDA $262K versus $(681)K.
Key corporate actions: acquisition of select assets from Laboratoire Provence-Canada for $775K cash (fair value $1,383K) including the Bacti Control brand, a newly signed exclusive 5-year supply agreement with a former LPC customer, and share repurchases under an NCIB (436,692 shares, $223K YTD). Cash ended at $8,308K.
Crescita Therapeutics (OTC:CRRTF) reported strong Q2 2025 financial results, with revenue increasing to $6.23 million, up from $4.09 million in Q2 2024. The company achieved a net income of $798,000 compared to a net loss of $926,000 in the prior year period. Key highlights include a significant improvement in Adjusted EBITDA to $964,000 from -$686,000.
The quarter featured a mutual termination agreement with Croma Pharma for Pliaglis® rights in certain European territories, contributing $902,000 to revenue. The company's Commercial Skincare segment showed growth, while Manufacturing segment benefited from new customer orders. Crescita maintained a strong cash position of $8.18 million and continued its share repurchase program, buying back 107,004 shares during Q2.
Crescita Therapeutics (TSX: CTX, OTC: CRRTF) reported its Q4 and fiscal 2024 financial results. Q4-2024 revenue increased to $6,902K from $4,725K, while recording a net loss of $(162K). For fiscal 2024, revenue grew to $19,580K from $17,522K, with a net loss of $(2,750K).
Key developments include: a new U.S. distribution agreement for Pliaglis with IPG Pharmaceuticals; a US$10M four-year manufacturing contract; an exclusive manufacturing agreement for sanitary products with potential annual revenue of $6M; and the acquisition of Occy Laboratoire's assets for $0.9M. The company maintained a strong cash position of $9.3M despite deploying over $2.0M for strategic acquisitions and equipment upgrades.
The company also initiated a Normal Course Issuer Bid to purchase up to 1,478,854 common shares and secured an exclusive distribution agreement with NanoPass Technologies for MicronJet in the Canadian medical aesthetics market.
Crescita Therapeutics reported Q3-2024 financial results with revenue of $3,594, up 18.5% from $3,033 in Q3-2023. The company saw improvements in net loss to $(1,036) from $(1,282) and Adjusted EBITDA to $(681) from $(988). Key developments include signing a US$10M four-year manufacturing agreement, securing an exclusive distribution agreement for MicronJet™600, and completing the acquisition of Occy Laboratoire assets. The company's cash position ended at $8,438, down $574 for the quarter.
Revenue growth was driven by the Skincare segment and higher Licensing revenue from Pliaglis® international launches. The company continues to prioritize securing a new U.S. partner for Pliaglis while focusing on manufacturing segment improvement.
Crescita Therapeutics Inc. (TSX: CTX, OTC US: CRRTF) has announced TSX approval for a new normal course issuer bid (NCIB). The company can purchase up to 1,478,854 common shares for cancellation, representing about 10% of its public float. Crescita believes the current market price may not reflect the company's underlying value and views share repurchases as a potential good use of funds.
Key details of the NCIB include:
- Daily purchase limit: 3,682 shares (25% of average daily trading volume)
- NCIB period: September 27, 2024 to September 26, 2025
- Purchases through TSX or Canadian alternative trading systems
- All purchased shares will be cancelled
Crescita has also entered an automatic securities purchase plan for the NCIB. In its previous NCIB (Aug 31, 2023 - Aug 30, 2024), the company bought 1,188,017 shares at an average price of $0.53.
Crescita Therapeutics Inc. (TSX: CTX, OTC US: CRRTF), a Canadian commercial dermatology company, will be presenting at the Planet MicroCap Showcase: VANCOUVER 2024 on Thursday, September 26, 2024, at 1:00 PM PST. CEO Serge Verreault will host the presentation and answer questions.
The event, held in association with Small Cap Discoveries, will take place at the Fairmont Waterfront Vancouver. Investors can access the live presentation via webcast and book 1x1 meetings with Crescita representatives. Registration is required for attendance and meeting scheduling.
This showcase provides Crescita an opportunity to connect with investors and showcase its growth-oriented, innovation-driven business model in the dermatology sector. For those unable to attend live, webcasts of company presentations will be available on the conference platform.
Crescita Therapeutics Inc. (TSX: CTX, OTC US: CRRTF) reported Q2-2024 financial results. Revenue decreased to $4,088 from $5,162 in Q2-2023, while gross profit declined to $2,235 from $3,069. Operating expenses remained stable at $3,279. The company secured a US$10 million manufacturing contract over 4 years and completed a strategic asset acquisition.
Key developments include:
- Amendment to contract manufacturer supply agreement
- Exclusive manufacturing deal with Canadian healthcare provider
- Distribution agreement for MicronJet™ intradermal injection device
- Acquisition of Occy Laboratoire assets for $0.9 million
Despite challenges in the Manufacturing segment, the Skincare business grew 10.7% year-over-year. The company maintains a strong cash position of $9,012, enabling investments for long-term value creation.